Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI


Primary Symbol: V.BTI.H Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by TheTruth1234on Apr 16, 2023 11:50am
151 Views
Post# 35397288

RE:Midatech General Meeting

RE:Midatech General Meeting
Boomskid wrote:
Midatech has issued a press release giving details of its upcoming general meeting. (Share consolidation, adjustment of recent financing prepaid warrant price, change in ADS ratio from 1:25 to 1:5, change in name to Biodexa, etc)
 
The information circular is available in PDF format here.
 
There is a PDF of Frequently Asked Questions that can be found here.
 
Today's share price, as I predicted, is down substantially and at 40¢ is approaching the 35¢ lower limit of the pricing adjustment of the prepaid warrants. The lower the share price, the more prepaid warrants will be issued. Approval of the agenda at the general meeting could lower the bottom limit of the adjustment price to 10¢.
 
The company is or can be controlled by the placees and there is no deal that can be made with Bioasis that can change that, meaning that former Midatech and Bioasis shareholders would have no control whatsoever over Biodexa.
 
I would suggest that Bioasis shareholders ask Graeme or DrDR whether Bioasis can enter a "merger" with Midatech/Biodexa without another vote on it by shareholders, or whether Bioasis considers that it already has approval of such a deal based on the recent AGM vote by shareholders.
 
If DrDR can do that and if it is done, you will be essentially wiped out. It is also possible (likely?) that Biodexa would not be able to retain ownership of the xB3 Platform. That would make it unlikely that Biodexa could offer much upside compared to whoever owns xB3. 
 
I won't be studying these documents in detail and likely won't comment on them further.
 
jd


"Today's share price, as I predicted"

But you didn't short Midatech did you JD??!

Always so smart, and always AFTER THE FACT. No one is as smart as you.

That is exactly why Dan got PAID by Bioasis and you did not.  That is why Dan isnt living broke in a Trailer having sold his entire networth in a scam penny stock just to eat.

You are pathetic. 

<< Previous
Bullboard Posts
Next >>